SAN FRANCISCO, CA--(Marketwire - July 09, 2012) - Audeo Oncology, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be sold and the price range for the proposed offering have not yet been determined.
Leerink Swann LLC and Oppenheimer & Co. Inc. will act as joint book-running managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, from the offices of Leerink Swann LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 telephone: 800-808-7525 ext. 4814; or Oppenheimer & Co. Inc., Attn: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY, 10004 telephone (212) 667-8563, or email: EquityProspectus@opco.com.
